New Experimental Drug Blocks Hep C Virus and Lowers Cholesterol | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Researchers Find a Way to Interrupt Hepatitis C Virus

Back to News Homepage
Next

Do You Want to Participate in a Hepatitis-C Clinical Trial?

New Experimental Drug Blocks Hep C Virus and Lowers Cholesterol

The Editors at Hepatitis Central
March 28, 2008

Print this page

By interfering with RNA, drug company Santaris may have launched a new generation of drugs. Following a successful animal trial, an unusual new drug has sparked interest due to its ability to lower cholesterol and block the Hepatitis C virus.

Drug lowers cholesterol and fights hepatitis C

By Steve Connor
Thursday, 27 March 2008
www.independent.co.uk

A drug that can lower cholesterol levels and prevent the liver from being attacked by the hepatitis C virus has come a step closer following a successful trial on laboratory animals.

The drug works in an unusual way by interfering with the natural genetic mechanism in the cells of the liver that keeps cholesterol levels high and – coincidentally – allows the hepatitis virus to replicate within the organ. The study, which was carried out on African green monkeys, lowered cholesterol levels by up to 40 per cent over three months with the help of just three intra-venous injections given over five days at the start of the trial.

Each injection contained a watery solution of a short, single-stranded molecule of RNA – a close relative of DNA – which found its way to the liver and bonded with a similar type of RNA which is found within the organ’s cells. This prevented the natural RNA from working normally, boosting the activity of certain genes, which lowered cholesterol and blocked the hepatitis C virus.

The study, published in Nature, was carried out by the Danish drug company Santaris. Scientists believe the findings support the idea of a new generation of drugs based on the ability to interfere with the natural functions of RNA.

Human trials of the new drug are expected to begin later this year.

No Comments - be the first!
Share
Share
Previous

Researchers Find a Way to Interrupt Hepatitis C Virus

Back to News Homepage
Next

Do You Want to Participate in a Hepatitis-C Clinical Trial?

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.